Trial Profile
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy With Intravitreal Injection of Lucentis (Ranibizumab Injection)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 Nov 2014
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation; Choroiditis; Degenerative myopia; Pseudoxanthoma elasticum; Retinal telangiectasis; Von Hippel-Lindau disease
- Focus Adverse reactions
- 15 Aug 2014 New trial record
- 24 Oct 2012
- 29 May 2007